Nefarma welcomes govt focus on ARE

2 April 2009

The Netherlands' drugmakers association, Nefarma, has welcomed the growing government focus on the problem of animal rights extremism, but  calls for tough measures against the perpetrators of violence and  intimidation towards pharmaceutical research firms and their employees.  The Nefarma's action comes in the wake of a report published in early  April by the General Intelligence and Security Service (AIVD), which  showed a rise in the number of animal rights actions.

Rise in ARE incidents in 2009

Michel Dutree, the Nefarma's director, noted that the UK had  successfully tackled the problem by imposing prison sentences on the  extremists found guilty of commiting terrorist actions. Since 2003, the  number of "home visits" in the UK has fallen from 259 to 10 last year.  By contrast, the AIVD found that, in the final quarter of 2008, the  number of ARE incidents was 15, but has risen sharply in the first three  months of 2009, to 23.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight